ArticleMolecular therapy. Oncology2024
Senescence-associated secretory phenotype regulation by dual-drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy.
Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EZH2 Regulates the Proliferation-Senescence Balance and Tumor-Stromal Signaling in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wang and colleagues provide a comprehensive evaluation of a biomimetic platform in which a specially designed drug delivery system, referred to in the manuscript as mPtP@Lipo, is used to increased penetration of dense stromatous tumors. This work represents a significant advancement in the treatment of desmoplastic tumors by targeting the tumor microenvironment (TME), particularly focusing on remodeling cancer-associated fibroblasts (CAFs). The study leverages previous work, which has demonstrated that platinum (Pt)-based chemotherapeutic regimens can induce a senescence-associated secretory phenotype (SASP) through persistent DNA damage, which can contribute to an immunosuppressive tumor immune microenvironment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.